X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1182) 1182
Book Review (332) 332
Publication (143) 143
Newsletter (6) 6
Book Chapter (5) 5
Newspaper Article (3) 3
Conference Proceeding (2) 2
Magazine Article (2) 2
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dasatinib (1057) 1057
index medicus (936) 936
humans (930) 930
oncology (547) 547
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (512) 512
imatinib (440) 440
chronic myeloid leukemia (433) 433
male (429) 429
hematology (414) 414
female (410) 410
protein kinase inhibitors - therapeutic use (396) 396
chronic myelogenous leukemia (386) 386
middle aged (376) 376
pyrimidines - therapeutic use (360) 360
pyrimidines - adverse effects (352) 352
nilotinib (337) 337
imatinib mesylate (331) 331
aged (330) 330
adult (325) 325
antineoplastic agents - therapeutic use (319) 319
protein kinase inhibitors - adverse effects (306) 306
chronic myeloid-leukemia (294) 294
treatment outcome (267) 267
thiazoles - therapeutic use (266) 266
leukemia (253) 253
thiazoles - adverse effects (249) 249
antineoplastic agents - adverse effects (242) 242
cancer (209) 209
care and treatment (206) 206
benzamides (198) 198
therapy (195) 195
tyrosine (188) 188
tyrosine kinase inhibitors (182) 182
piperazines - therapeutic use (179) 179
pyrimidines - administration & dosage (177) 177
tyrosine kinase inhibitor (176) 176
protein-tyrosine kinases - antagonists & inhibitors (174) 174
research (173) 173
bcr-abl (163) 163
drug therapy (155) 155
follow-up (155) 155
aged, 80 and over (152) 152
protein kinase inhibitors - administration & dosage (148) 148
hemic and lymphatic diseases (146) 146
medicine & public health (142) 142
pharmacology & pharmacy (138) 138
chronic-phase (137) 137
thiazoles - administration & dosage (127) 127
cml (125) 125
dosage and administration (125) 125
piperazines - adverse effects (125) 125
antineoplastic agents - administration & dosage (123) 123
young adult (123) 123
cytogenetic responses (118) 118
drug resistance, neoplasm (117) 117
animals (108) 108
antineoplastic agents (106) 106
dasatinib - therapeutic use (106) 106
mutation (105) 105
protein kinase inhibitors - pharmacology (105) 105
analysis (101) 101
hematology, oncology and palliative medicine (101) 101
antimitotic agents (100) 100
fusion proteins, bcr-abl - genetics (97) 97
imatinib-resistant (97) 97
leukemia, myelogenous, chronic, bcr-abl positive - genetics (97) 97
adolescent (96) 96
dasatinib - adverse effects (96) 96
leukemia, myelogenous, chronic, bcr-abl positive - pathology (96) 96
antineoplastic combined chemotherapy protocols - therapeutic use (95) 95
pyrimidines - pharmacology (94) 94
patients (92) 92
chemotherapy (90) 90
resistance (89) 89
risk factors (89) 89
fusion proteins, bcr-abl - antagonists & inhibitors (84) 84
leukemia, myeloid, chronic-phase - drug therapy (84) 84
article (83) 83
antineoplastic agents - pharmacology (82) 82
complications and side effects (81) 81
kinases (81) 81
health aspects (80) 80
protein-tyrosine kinase (77) 77
abridged index medicus (76) 76
philadelphia chromosome (76) 76
retrospective studies (73) 73
piperazines - administration & dosage (71) 71
bosutinib (70) 70
clinical trials as topic (70) 70
tyrosine kinase (69) 69
disease-free survival (68) 68
acute lymphoblastic-leukemia (67) 67
clinical trials (67) 67
follow-up studies (67) 67
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (67) 67
prognosis (65) 65
kinase inhibitor (60) 60
survival (60) 60
genetic aspects (59) 59
patient outcomes (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1149) 1149
Japanese (17) 17
Chinese (9) 9
French (6) 6
German (4) 4
Spanish (4) 4
Russian (2) 2
Danish (1) 1
Hebrew (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
International Journal of Dermatology, ISSN 0011-9059, 03/2018, Volume 57, Issue 3, pp. 332 - 338
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 10/2011, Volume 118, Issue 17, pp. 4567 - 4576
Journal Article
Circulation, ISSN 0009-7322, 05/2012, Volume 125, Issue 17, pp. 2128 - 2137
Background-The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases of precapillary PH have been reported in... 
Dasatinib | Chronic myeloid leukemia | Vascular complications | Adverse drug events | Pulmonary hypertension | CHRONIC MYELOGENOUS LEUKEMIA | LONG-TERM | SURVIVAL | CARDIAC & CARDIOVASCULAR SYSTEMS | MYELOPROLIFERATIVE DISORDERS | INHIBITORS IMATINIB | pulmonary hypertension | TYROSINE KINASE | CELL-GROWTH | FAILURE | NILOTINIB | CHRONIC MYELOID-LEUKEMIA | adverse drug events | vascular complications | dasatinib | chronic myeloid leukemia | PERIPHERAL VASCULAR DISEASE | Hypertension, Pulmonary - diagnosis | Follow-Up Studies | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Hypertension, Pulmonary - chemically induced | Thiazoles - adverse effects | Antineoplastic Agents - adverse effects | Adult | Female | Registries | Antineoplastic Agents - pharmacology | Hypertension, Pulmonary - drug therapy | Drug Utilization - statistics & numerical data | Endothelin Receptor Antagonists | Bone Morphogenetic Protein Receptors, Type II - genetics | Adverse Drug Reaction Reporting Systems | Treatment Outcome | Piperazines - therapeutic use | Hypertension, Pulmonary - epidemiology | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - adverse effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Pyrimidines - adverse effects | Hydroxyurea - therapeutic use | Aged | Hemodynamics - drug effects | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Care and treatment | Dosage and administration | Drug therapy | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2015, Volume 168, Issue 1, pp. 69 - 81
Bosutinib is an oral, dual SRC / ABL 1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia ( CML ). We assessed the efficacy and... 
BCR‐ABL1 | CML | tyrosine kinase inhibitor | bosutinib | chronic myeloid leukaemia | Chronic myeloid leukaemia | Tyrosine kinase inhibitor | Bosutinib | BCR-ABL1 | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | MOLECULAR RESPONSES | DASATINIB | NILOTINIB | RESISTANT | INTERFERON-ALPHA | IN-VITRO | PATIENTS RECEIVING IMATINIB | INHIBITOR | HEMATOLOGY | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Odds Ratio | Benzamides - adverse effects | Aniline Compounds - administration & dosage | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Index Medicus | Haematological Malignancy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Summary Background Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment, although it is associated... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | EARLY MOLECULAR RESPONSE | INTERFERON | ONCOLOGY | BOSUTINIB | RESISTANCE | TYROSINE KINASE INHIBITOR | FOLLOW-UP | DASATINIB | BCR-ABL1 TRANSCRIPT | NILOTINIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Imatinib Mesylate - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Imatinib Mesylate - administration & dosage | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Philadelphia Chromosome - drug effects | Pyridazines - adverse effects | Imidazoles - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Fusion Proteins, bcr-abl - genetics | Adolescent | Aged | Drug-Related Side Effects and Adverse Reactions - classification | Antimitotic agents | Clinical trials | Medical colleges | Product development | Research institutes | Antineoplastic agents | Analysis | Index Medicus | Life Sciences | Cancer
Journal Article
Blood, ISSN 0006-4971, 02/2012, Volume 119, Issue 5, pp. 1123 - 1129
Journal Article
Blood, ISSN 0006-4971, 07/2016, Volume 128, Issue 4, pp. 504 - 507
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2015, Volume 90, Issue 4, pp. E66 - E72
Rare but serious cardiovascular and pulmonary adverse events ( AEs ) have been reported in patients with chronic myeloid leukemia treated with BCR‐ABL... 
CHRONIC PHASE | DASATINIB TREATMENT | NILOTINIB THERAPY | PLEURAL EFFUSION | VASCULAR EVENTS | DATABASES | ARTERIAL OCCLUSIVE DISEASE | HYPERTENSION | HEMATOLOGY | IMATINIB MESYLATE | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Lung Diseases - chemically induced | United States | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Thiazoles - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Thiazoles - therapeutic use | Thiazoles - adverse effects | Young Adult | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Cardiovascular Diseases - epidemiology | Product Surveillance, Postmarketing | Adult | Benzamides - adverse effects | United States Food and Drug Administration | Databases, Factual | Dasatinib | Adverse Drug Reaction Reporting Systems | Pyrimidines - administration & dosage | Logistic Models | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Cardiovascular Diseases - chemically induced | Lung Diseases - epidemiology | Care and treatment | Data mining | Drug approval | Analysis | Leukemia | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 07/2015, Volume 126, Issue 1, pp. 42 - 49
Journal Article